Seasonal Allergic Rhinitis Clinical Trial
— FEXPRESAROfficial title:
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Verified date | November 2023 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.
Status | Completed |
Enrollment | 94 |
Est. completion date | March 14, 2023 |
Est. primary completion date | March 14, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Participants are eligible to be included in the study only if all of the following criteria apply: - Participant is willing to provide written informed consent. - Adult participants (18 to 80 years old) suffering from SAR provoked by Ragweed pollen. - Participants having a TNSS-3 =4 (with 3 nasal symptoms) at first pollen challenge at Visit 2. - Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control). Exclusion Criteria: - History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting ß2agonists, less than 2 doses per week can be enrolled. - History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. - History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system. - Presence or history of drug hypersensitivity to fexofenadine and/or its excipients. - Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge: - Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines. - Intranasal or inhaled corticosteroids: 7 days. - Ocular, intranasal, or inhaled sodium cromoglycate: 14 days. - High doses of systemic corticosteroids: 30 days. - Leukotriene antagonists: 30 days. - Intranasal or systemic decongestants: 3 days. - Tricyclic antidepressants: 7 days. - Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days. - Aluminum-and-magnesium containing antacids: 7 days. - Omalizumab/dupilumab: within 6 months - Any contraindications to fexofenadine, according to the labeling. - The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Canada | Investigational Site Number : 1240001 | Kingston | Ontario |
Lead Sponsor | Collaborator |
---|---|
Opella Healthcare Group SAS, a Sanofi Company |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC of the total nasal symptoms score (TNSS-3) | Area under the plasma concentration-time curve (AUC) of TNSS-3 The total nasal symptom score of 3 symptoms (TNSS-3: scale of each symptom is scored from 0 to 3): rhinorrhea, sneezing, and nasal itching scores. | from 0 hour to 6 hours at day 4 | |
Secondary | AUC of total ocular symptoms score (TOSS) (0h-6h at day 4) | TOSS = Total Ocular Symptoms Score. | from 0 hour to 6 hours at day 4 | |
Secondary | AUC of total nasal symptoms score (TNSS-3) (0h-12h at day 4) | from 0 hour to 12 hours at day 4 | ||
Secondary | AUC of total ocular symptoms score (TOSS) (0h-12h at day 4) | from 0 hour to 12 hours at day 4 | ||
Secondary | AUC of total nasal symptoms score (TNSS-3) (Day 1 to day 4) | from randomization (day 1 ) to day 4 | ||
Secondary | AUC of total ocular symptoms score (TOSS) (Day 1 to day 4) | from randomization (day 1) to day 4 | ||
Secondary | Percentage of participants with Adverse Events | from screening to day 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01171664 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
|
Phase 2 | |
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT00784732 -
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00578929 -
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
|
Phase 3 | |
Completed |
NCT00619827 -
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
|
Phase 1 | |
Completed |
NCT00209365 -
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
|
N/A | |
Terminated |
NCT00223587 -
Seasonal Allergic Rhinitis and Driving Ability
|
Phase 4 | |
Completed |
NCT00637455 -
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
|
Phase 4 | |
Completed |
NCT00963599 -
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
|
Phase 3 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT06126952 -
Azelastine Allergen Chamber - Onset of Action Study
|
Phase 2 | |
Completed |
NCT02245360 -
Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01940146 -
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT01230619 -
Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
|
Phase 2 | |
Completed |
NCT00561717 -
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
Completed |
NCT00420082 -
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
|
Phase 2 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT00443495 -
Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis
|
Phase 1/Phase 2 | |
Completed |
NCT03097432 -
Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment
|
N/A |